ClinicalTrials.gg
CompletedNCT04496167Updated Sep 13, 2023Results posted

Safety and Efficacy of EN3835 in Participants With Frozen Shoulder

A Phase 2 interventional study of EN3835 and Placebo in Adhesive Capsulitis and Frozen Shoulder, sponsored by Endo Pharmaceuticals. Completed at 38 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-13.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 45 studies in Bursitis with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Bursitis · United States.

Enrollment
11th of 41
198 · median 40
Started
2020
with 5 others
Phase 2
6 of 45
none open now
Registered
35th of 45
by date
Lead sponsor
4 of 45
Endo Pharmaceuticals

Among the 45 studies in Bursitis with a site in United States, this one is the 11th largest by enrollment of the 41 interventional ones that give a count, is one of 6 that started in 2020, is one of 6 in phase 2, and was the 35th registered.

Bursitis

383 studies on the registry are indexed under Bursitis; 111 are open to participants now.

Browse Bursitis studies →

Open to participants now

4 of the 45 studies in Bursitis with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 64 Bursitis studies recruiting now, 17 (27%) set no upper age limit and 40 (63%) stop at 75 or younger; none take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Bursitis with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of EN3835 for the treatment of adhesive capsulitis of the shoulder (frozen shoulder).

03

Conditions studied

  • Adhesive Capsulitis
  • Frozen Shoulder

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have idiopathic unilateral adhesive capsulitis (also known as frozen shoulder).
  2. Have unaffected range of motion in the contralateral shoulder as determined by the investigator.
  3. Be willing to undergo x-ray and magnetic resonance imaging (MRI) of both affected and unaffected shoulder.
  4. Agree to participate in supervised, in-office physical therapy sessions and to complete home exercises at designated time points during the study.
  5. Agree to avoid general lifting and carrying during the study as instructed.
  6. Be able to read, understand, and independently complete participant reported outcome instruments in English.
  7. If female, be of non- (history of hysterectomy, bilateraloophorectomy, bilateral tubal ligation, or with no history of menstrual flow in the 12 months prior to the Screening Visit); or, if of childbearing potential, be non-pregnant, non-lactating and agree to use effective when with a male partner for the duration of the study (and for 28 days after any active treatment period for participant who early terminate). Acceptable forms of contraception include hormonal measures (oral contraceptive pills, contraceptive patch, contraceptive ring, and injections), intrauterine devices, double barrier method (condom plus diaphragm, condom or diaphragm plus spermicidal gel or foam), surgical sterilization of the male partner, and abstinence.
  8. If male with , agree to use effective contraception (abstinence, surgical sterilization [vasectomy], or condom with spermicide) with a female partner of child-bearing potential for the duration of the study (and for 28 days after any active treatment period for participant who early terminate).
  9. Be willing and able to cooperate with the requirements of the study.
  10. Be adequately informed and understand the nature and risks of the study and be able to provide consent .

Exclusion criteria

Exclusion Criteria:

  1. Has a known allergy to collagenase or any other of EN3835 or any other procedural medication (including local anesthetics).
  2. Has received treatment for adhesive capsulitis (in the timeframes outlined below) or is planning to receive any treatment (other than study treatment) for adhesive capsulitis at any time during the study in the affected shoulder, including but not limited to:

    • Physical therapy or acupuncture within 2 weeks before the first injection of study treatment.
    • Intra-articular or intrabursal injection(s) of lidocaine, suprascapular nerve blocks, or electroanalgesic and/or thermoanalgesic modalities within 1 month before the Screening Visit.
    • Intra-articular or intrabursal injection(s) of within 8 weeks before the Screening Visit.
    • Intra-articular or intrabursal injection(s) of sodium hyaluronate and/or glenohumeral distension arthrography within 3 months before the Screening Visit.
    • Manipulation under anaesthesia at any time prior to the study.
    • Surgery (including arthroscopic or open capsular release, capsulectomy, or capsulotomy) at any time prior to the study.
  3. Has any abnormalities/conditions in the affected shoulder that would be potentially confounding as determined by the central MRI review committee grading criteria.
  4. Has a prosthesis or replacement of right or left shoulder, elbow, wrist, and/or hand.
  5. Has systemic conditions (, hypertension, diabetes, thyroid disease, thrombosis, physical impairment, infection, significant medical condition) that restricts study participation.
  6. Has any for MRI (implant containing metal, internal metallic object, permanent cosmetics/make-up/tattoos, claustrophobia, anemia, uncontrolled hypertension, epilepsy, asthma, sickle cell disease) as determined by the technologist, the radiologist, and/or investigator performing the imaging, with exemption of the area to be treated/reviewed.
  7. Has a known coagulation disorder or is taking any medications that would increase the risk of bleeding (except \<150 milligrams of aspirin daily), 7 days prior to first injection and for the duration of the study.
  8. Has received oral or parenteral steroids for any reason within 3 weeks before the Screening Visit.
  9. Has, at any time, received collagenase for the treatment of adhesive capsulitis (including participant who received treatment in Study AUX-CC-870 or AUX-CC-871).
  10. Has received treatment with an product within 30 days (or 5 half lives, whichever is longer) of the screening visit.
  11. Has received collagenase treatments (for example, Santyl® ointment and/or XIAFLEX/XIAPEX®) for any other indication within 30 days prior to study treatment administration, or is planning to be treated with collagenase (other than study treatment) at any time during the study.
  12. Has donated blood within 30 days prior to the Screening Visit or has plans to donate blood during the study.
  13. Has a interval (QTc) of ≥ 450 milliseconds (ms) for male participant or ≥470 ms for female participant on the screening (ECG).
  14. Is from a vulnerable population, as defined by the US Code of Federal Regulations (CFR) Title 45, Part 46, Section 46.111(b) and other local and national regulations, including but not limited to, employees (temporary, part-time, full-time, etc) or a family member of the research staff conducting the study, or of the sponsor, or of the contract research organization, or of the Institutional Review Board (IRB)/Independent Ethics Committee (IEC).
  15. Has concurrent diseases that might interfere with the conduct of the study, confound the interpretation of the study results, or endanger the participant's well-being, (for example, evidence of any significant hematological, endocrine, cardiovascular, respiratory, neurological, renal, hepatic, or gastrointestinal disease). If there is a history of such disease but the condition has been stable for more than 5 year(s) and is judged by the investigator not to interfere with the participant's participation in the study, the participant may be included, with the documented approval of the Medical Monitor.
  16. Has any other condition(s) that, in the investigator's opinion, might indicate the participant to be unsuitable for the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
198 participants (actual)

Study arms

  • Experimental
    EN3835

    EN3835 up to 1.74 mg

    Drug: EN3835

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • DrugEN3835

    Collagenase clostridium histolyticum

  • DrugPlacebo

    Placebo comparator

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Adapted American Shoulder and Elbow Surgeons Shoulder Assessment Form (ASES) Composite Score for the Affected Shoulder at Day 95

    Adapted ASES is a self-administered participant reported outcome measure, divided into 2 sections: pain and function. Pain subscale is a single item, 11-point numeric rating scale, ranging from 0 (no pain at all) to 10 (worst pain), calculated as 10 - pain raw score and multiplying by 5, score ranging from 0 (worst pain) to 50 (no pain). Function subscale consists of 10 activities, 4-point ordinal scale about their ability to do the activity with the affected arm, ranging from 0 (unable to do) to 3 (not difficult), calculated by multiplying total score for 10 items by 5 and then dividing it by 3, score range of 0 (no function) to 50 (full function). Adapted ASES composite score is the sum of the pain subscale score (50% of the composite score) and function subscale score (50% of the composite score), score range of 0 (worst pain) to 100 (least pain). Positive change from Baseline score means an improvement in pain and/or shoulder function.

    Time frame: Baseline, Day 95

Secondary outcomes

  1. Change From Baseline in Passive Range of Motion (PROM) for Forward Flexion in the Affected Shoulder

    PROM for forward flexion was measured using a goniometer. Positive change from Baseline means an improvement.

    Time frame: Baseline, Days 22, 43, 64, and 95

  2. Change From Baseline in PROM for Internal Rotation in the Affected Shoulder

    PROM for internal rotation was measured using a goniometer and a spinal level. Positive change from Baseline means an improvement.

    Time frame: Baseline, Days 22, 43, 64, and 95

  3. Change From Baseline in PROM for External Rotation in the Affected Shoulder

    PROM for external rotation was measured using a goniometer. Positive change from Baseline means an improvement.

    Time frame: Baseline, Days 22, 43, 64, and 95

  4. Change From Baseline in PROM for Abduction in the Affected Shoulder

    PROM for abduction was measured using a goniometer. Positive change from Baseline means an improvement.

    Time frame: Baseline, Days 22, 43, 64, and 95

  5. Change From Baseline in PROM for Shoulder Extension in the Affected Shoulder

    PROM for shoulder extension was measured using a goniometer. Positive change from Baseline means an improvement.

    Time frame: Baseline, Days 22, 43, 64, and 95

  6. Change From Baseline in PROM for Forward Flexion in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline

    PROM for forward flexion was measured using a goniometer. PROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. PROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value

    Time frame: Baseline, Days 22, 43, 64, and 95

  7. Change From Baseline in PROM for Internal Rotation in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline

    PROM for internal rotation was measured using a goniometer and a spinal level. PROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. PROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value

    Time frame: Baseline, Days 22, 43, 64, and 95

  8. Change From Baseline in PROM for External Rotation in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline

    PROM for external rotation was measured using a goniometer PROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. PROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value

    Time frame: Baseline, Days 22, 43, 64, and 95

  9. Change From Baseline in PROM for Abduction in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline

    PROM for abduction was measured using a goniometer. PROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. PROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value

    Time frame: Baseline, Days 22, 43, 64, and 95

  10. Change From Baseline in PROM for Shoulder Extension in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline

    PROM for shoulder extension was measured using a goniometer. PROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. PROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value

    Time frame: Baseline, Days 22, 43, 64, and 95

  11. Change From Baseline in Active Range of Motion (AROM) for Forward Flexion in the Affected Shoulder

    AROM for forward flexion was measured using a goniometer. Positive change from Baseline means an improvement.

    Time frame: Baseline, Days 22, 43, 64, and 95

  12. Change From Baseline in AROM for Internal Rotation in the Affected Shoulder

    AROM for internal rotation was measured using a goniometer and a spinal level. Positive change from Baseline means an improvement.

    Time frame: Baseline, Days 22, 43, 64, and 95

  13. Change From Baseline in AROM for External Rotation in the Affected Shoulder

    AROM for external rotation was measured using a goniometer. Positive change from Baseline means an improvement.

    Time frame: Baseline, Days 22, 43, 64, and 95

  14. Change From Baseline in AROM for Abduction in the Affected Shoulder

    AROM for abduction was measured using a goniometer. Positive change from Baseline means an improvement.

    Time frame: Baseline, Days 22, 43, 64, and 95

  15. Change From Baseline in AROM for Shoulder Extension in the Affected Shoulder

    AROM for shoulder extension was measured using a goniometer. Positive change from Baseline means an improvement.

    Time frame: Baseline, Days 22, 43, 64, and 95

  16. Change From Baseline in AROM for Forward Flexion in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline

    AROM for forward flexion was measured using a goniometer. AROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. AROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value

    Time frame: Baseline, Days 22, 43, 64, and 95

  17. Change From Baseline in AROM for Internal Rotation in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline

    AROM for internal rotation was measured using a goniometer and a spinal level. AROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. AROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value

    Time frame: Baseline, Days 22, 43, 64, and 95

  18. Change From Baseline in AROM for External Rotation in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline

    AROM for external rotation was measured using a goniometer. AROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. AROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value

    Time frame: Baseline, Days 22, 43, 64, and 95

  19. Change From Baseline in AROM for Abduction in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline

    AROM for abduction was measured using a goniometer. AROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. AROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value

    Time frame: Baseline, Days 22, 43, 64, and 95

  20. Change From Baseline in AROM for Shoulder Extension in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline

    AROM for shoulder extension was measured using a goniometer. AROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. AROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value

    Time frame: Baseline, Days 22, 43, 64, and 95

  21. Change From Baseline in the Adapted ASES Composite Score

    The adapted ASES is a self-administered participant reported outcome measure, divided into 2 sections: pain and function. Pain subscale is a single item, 11-point numeric rating scale, ranging from (no pain at all) to 10 (worst pain), calculated as 10 - pain raw score and multiplying by 5, score ranging from 0 (worst pain) to 50 (no pain). Function subscale consists of 10 activities, 4-point ordinal scale about their ability to do the activity with the affected arm, ranging from 0 (unable to do) to 3 (not difficult), calculated by multiplying the total score for 10 items by 5 and then dividing it by 3, score ranging from 0 (no function) to 50 (full function). The adapted ASES composite score is the sum of the pain subscale score (50% of the composite score) and function subscale score (50% of the composite score). The range for composite score is 0 (worst pain) to 100 (least pain). Positive change from Baseline score means an improvement in pain and/or shoulder function.

    Time frame: Baseline, Day 22, 43, and 64

  22. Change From Baseline in the Adapted ASES Function Subscale Score

    The adapted ASES function subscale consists of 10 activities, 4-point ordinal scale about their ability to do the activity with the affected arm, ranging from 0 (unable to do) to 3 (not difficult), calculated by multiplying the total score for 10 items by 5 and then dividing it by 3, score ranging from 0 (worst no function) to 50 (full function). Positive change from Baseline score means an improvement in shoulder function.

    Time frame: Baseline, Day 22, 43, 64, and 95

  23. Change From Baseline in the Adapted ASES Pain Subscale Score

    The adapted ASES pain subscale is a single item, 11-point numeric rating scale, ranging from (no pain at all) to 10 (worst pain), calculated as 10 - pain raw score and multiplying by 5, score ranging from 0 (worst pain) to 50 (no pain). Positive change from Baseline score means an improvement in shoulder pain.

    Time frame: Baseline, Day 22, 43, 64, and 95

  24. Change From Baseline in the Pain Upon Movement (PUM) Scale Score for the Affected Shoulder

    The PUM scale is a single item 11-point numerical rating scale of pain in the affected shoulder after AROM forward flexion, internal rotation, external rotation, abduction, and shoulder extension on a scale from 0 (no pain at all) to 10 (pain as bad as it can be). A decrease from Baseline indicates improvement.

    Time frame: Baseline, Days 64 and 95

  25. Change From Baseline in Patient-reported Global Severity of Adhesive Capsulitis Scale

    The Patient-reported Global Severity of Adhesive Capsulitis is a single item, 11-point numerical rating scale that asks participants to rate the overall severity of their adhesive capsulitis symptoms on a scale from 0 (no severity) to 10 (severe as can be). A decrease from Baseline indicates improvement.

    Time frame: Baseline, Day 22, 43, 64, and 95

  26. Patient-reported Change in Severity of Adhesive Capsulitis Scale

    The Patient-reported Change in Severity of Adhesive Capsulitis is a questionnaire that asks participants if their adhesive capsulitis symptoms are "Better, About the Same, or Worse" since the last time the questionnaire was administered. Participants who reported that their symptoms are better or worse are then asked to rate the change in their symptoms on a 7-point ordinal scale for worse and better severity. An overall severity of worse was rated from 0 (almost the same, hardly worse at all) to -6 (a very great deal worse). An overall severity of better was rated from 0 (almost the same, hardly better at all) to 6 (a very great deal better). Only participants with a response of 'Worse' or 'Better' were analyzed. Participants with an overall severity response of 'About the same' were excluded from the summary table below. For overall worse severity, a lower score indicated a worse outcome. For overall better severity, a higher score indicated a better outcome.

    Time frame: Days 22, 43, 64 and 95

  27. Number of Responders Assessed With Investigator Assessment of Improvement

    Investigator assessment of improvement with treatment in the severity of the participant's treated shoulder using a 7-point Likert scale from very much worse (-3) to very much improved (3). A responder was defined as a response of "very much improved", "much improved" or "minimally improved" in the investigator assessment of improvement with treatment.

    Time frame: Days 64 and 95

  28. Number of Responders Assessed by the Subject Satisfaction With Treatment Assessment

    Participants rated their satisfaction with treatment on a 7-point Likert scale from very dissatisfied (-3) to very satisfied (3) at specified times for relief of pain in treated shoulder, relief of stiffness in treated shoulder, relief of pain in treated shoulder compared to better shoulder, and relief of stiffness in treated shoulder compared to better shoulder. A responder was defined as a participant with a response of "very satisfied", "satisfied" or "somewhat satisfied" in the satisfaction with treatment.

    Time frame: Days 64 and 95

  29. Number of Participants Positive for Anti-AUX-I and Anti-AUX-II Antibodies

    Serum samples were collected and tested for the presence of anti-AUX-I and anti-AUX-II antibodies.

    Time frame: Day 95

  30. Number of Participants Positive for Neutralizing Antibodies

    Serum samples were collected and tested for the presence of anti-AUX-I and anti-AUX-II antibodies. Only samples positive for anti-AUX-I and anti-AUX-II antibodies were analyzed for neutralizing antibodies.

    Time frame: Day 95

07

Results

Posted Sep 13, 2023

Participant flow

Participant flow — Overall Study
MilestoneEN3835Placebo
Started10296
Received at least 1 dose of study drug10194
Completed8480
Not completed1816
Withdrew: Adverse event62
Withdrew: Withdrawal by subject76
Withdrew: Lost to follow-up35
Withdrew: Not treated12
Withdrew: Other than specified11

Outcome measures

PrimaryChange From Baseline in the Adapted American Shoulder and Elbow Surgeons Shoulder Assessment Form (ASES) Composite Score for the Affected Shoulder at Day 95

Adapted ASES is a self-administered participant reported outcome measure, divided into 2 sections: pain and function. Pain subscale is a single item, 11-point numeric rating scale, ranging from 0 (no pain at all) to 10 (worst pain), calculated as 10 - pain raw score and multiplying by 5, score ranging from 0 (worst pain) to 50 (no pain). Function subscale consists of 10 activities, 4-point ordinal scale about their ability to do the activity with the affected arm, ranging from 0 (unable to do) to 3 (not difficult), calculated by multiplying total score for 10 items by 5 and then dividing it by 3, score range of 0 (no function) to 50 (full function). Adapted ASES composite score is the sum of the pain subscale score (50% of the composite score) and function subscale score (50% of the composite score), score range of 0 (worst pain) to 100 (least pain). Positive change from Baseline score means an improvement in pain and/or shoulder function.

Time frame:
Baseline, Day 95
Reported as:
Mean · score on a scale
Change From Baseline in the Adapted American Shoulder and Elbow Surgeons Shoulder Assessment Form (ASES) Composite Score for the Affected Shoulder at Day 95
score on a scaleEN3835Placebo
Change From Baseline in the Adapted American Shoulder and Elbow Surgeons Shoulder Assessment Form (ASES) Composite Score for the Affected Shoulder at Day 9541.35 ± 22.43241.16 ± 21.942
Statistical analysis
  • EN3835 vs Placebo · MMRM · p = 0.659 (Considered significant if p-value is less than 0.05.) · Least square mean treatment difference: 1.386 · 95% CI -4.804 to 7.577The model included treatment, visit and interaction of treatment, visit as fixed effects, Baseline as a covariate, and repeated measures with visit/participant. Treatment difference: EN3835 - Placebo
SecondaryChange From Baseline in Passive Range of Motion (PROM) for Forward Flexion in the Affected Shoulder

PROM for forward flexion was measured using a goniometer. Positive change from Baseline means an improvement.

Time frame:
Baseline, Days 22, 43, 64, and 95
Reported as:
Mean · degrees
Change From Baseline in Passive Range of Motion (PROM) for Forward Flexion in the Affected Shoulder
degreesEN3835Placebo
Day 2219.1 ± 24.8813.9 ± 22.40
Day 4325.6 ± 26.8921.4 ± 20.14
Day 6431.4 ± 26.3127.3 ± 23.68
Day 9532.8 ± 25.5929.7 ± 27.08
SecondaryChange From Baseline in PROM for Internal Rotation in the Affected Shoulder

PROM for internal rotation was measured using a goniometer and a spinal level. Positive change from Baseline means an improvement.

Time frame:
Baseline, Days 22, 43, 64, and 95
Reported as:
Mean · degrees
Change From Baseline in PROM for Internal Rotation in the Affected Shoulder
degreesEN3835Placebo
Day 226.9 ± 23.957.0 ± 17.94
Day 4311.0 ± 25.9712.4 ± 19.92
Day 6418.0 ± 24.6518.3 ± 21.95
Day 9519.9 ± 22.5921.6 ± 23.11
SecondaryChange From Baseline in PROM for External Rotation in the Affected Shoulder

PROM for external rotation was measured using a goniometer. Positive change from Baseline means an improvement.

Time frame:
Baseline, Days 22, 43, 64, and 95
Reported as:
Mean · degrees
Change From Baseline in PROM for External Rotation in the Affected Shoulder
degreesEN3835Placebo
Day 227.3 ± 19.398.8 ± 15.61
Day 4311.2 ± 20.9814.5 ± 18.87
Day 6417.4 ± 24.8717.8 ± 17.87
Day 9519.1 ± 21.2419.2 ± 18.20
SecondaryChange From Baseline in PROM for Abduction in the Affected Shoulder

PROM for abduction was measured using a goniometer. Positive change from Baseline means an improvement.

Time frame:
Baseline, Days 22, 43, 64, and 95
Reported as:
Mean · degrees
Change From Baseline in PROM for Abduction in the Affected Shoulder
degreesEN3835Placebo
Day 2215.6 ± 28.4713.1 ± 23.89
Day 4329.6 ± 30.1918.9 ± 27.13
Day 6435.6 ± 36.7631.1 ± 29.27
Day 9542.1 ± 38.1736.0 ± 33.35
SecondaryChange From Baseline in PROM for Shoulder Extension in the Affected Shoulder

PROM for shoulder extension was measured using a goniometer. Positive change from Baseline means an improvement.

Time frame:
Baseline, Days 22, 43, 64, and 95
Reported as:
Mean · degrees
Change From Baseline in PROM for Shoulder Extension in the Affected Shoulder
degreesEN3835Placebo
Day 223.9 ± 16.515.7 ± 13.54
Day 438.0 ± 18.349.2 ± 16.93
Day 6415.2 ± 18.4412.0 ± 17.23
Day 9520.3 ± 18.3014.7 ± 17.15
SecondaryChange From Baseline in PROM for Forward Flexion in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline

PROM for forward flexion was measured using a goniometer. PROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. PROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value

Time frame:
Baseline, Days 22, 43, 64, and 95
Reported as:
Mean · degrees
Change From Baseline in PROM for Forward Flexion in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline
degreesEN3835Placebo
Day 22-34.48 ± 29.067-37.33 ± 27.179
Day 43-28.34 ± 27.939-30.24 ± 26.369
Day 64-22.14 ± 27.983-23.01 ± 24.200
Day 95-20.82 ± 26.245-21.06 ± 25.198
SecondaryChange From Baseline in PROM for Internal Rotation in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline

PROM for internal rotation was measured using a goniometer and a spinal level. PROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. PROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value

Time frame:
Baseline, Days 22, 43, 64, and 95
Reported as:
Mean · degrees
Change From Baseline in PROM for Internal Rotation in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline
degreesEN3835Placebo
Day 22-30.76 ± 24.692-28.51 ± 24.930
Day 43-26.81 ± 24.950-22.03 ± 24.311
Day 64-20.50 ± 21.561-16.88 ± 24.096
Day 95-18.22 ± 21.444-13.49 ± 26.037
SecondaryChange From Baseline in PROM for External Rotation in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline

PROM for external rotation was measured using a goniometer PROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. PROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value

Time frame:
Baseline, Days 22, 43, 64, and 95
Reported as:
Mean · degrees
Change From Baseline in PROM for External Rotation in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline
degreesEN3835Placebo
Day 22-35.12 ± 22.928-35.49 ± 23.027
Day 43-31.30 ± 25.102-29.40 ± 25.727
Day 64-24.46 ± 26.063-26.08 ± 24.494
Day 95-22.94 ± 22.153-25.06 ± 23.844
SecondaryChange From Baseline in PROM for Abduction in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline

PROM for abduction was measured using a goniometer. PROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. PROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value

Time frame:
Baseline, Days 22, 43, 64, and 95
Reported as:
Mean · degrees
Change From Baseline in PROM for Abduction in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline
degreesEN3835Placebo
Day 22-54.90 ± 40.162-57.56 ± 35.565
Day 43-41.37 ± 39.918-53.17 ± 36.106
Day 64-34.87 ± 39.860-41.48 ± 37.136
Day 95-28.91 ± 41.483-36.54 ± 41.288
SecondaryChange From Baseline in PROM for Shoulder Extension in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline

PROM for shoulder extension was measured using a goniometer. PROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. PROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value

Time frame:
Baseline, Days 22, 43, 64, and 95
Reported as:
Mean · degrees
Change From Baseline in PROM for Shoulder Extension in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline
degreesEN3835Placebo
Day 22-18.82 ± 21.558-17.11 ± 19.106
Day 43-14.99 ± 22.313-14.01 ± 20.363
Day 64-7.97 ± 22.633-9.91 ± 18.869
Day 95-2.87 ± 20.756-7.33 ± 17.676
SecondaryChange From Baseline in Active Range of Motion (AROM) for Forward Flexion in the Affected Shoulder

AROM for forward flexion was measured using a goniometer. Positive change from Baseline means an improvement.

Time frame:
Baseline, Days 22, 43, 64, and 95
Reported as:
Mean · degrees
Change From Baseline in Active Range of Motion (AROM) for Forward Flexion in the Affected Shoulder
degreesEN3835Placebo
Day 2213.6 ± 26.2813.0 ± 26.55
Day 4321.9 ± 30.0022.3 ± 26.17
Day 6427.7 ± 25.4729.6 ± 28.85
Day 9531.7 ± 25.3130.1 ± 31.20
SecondaryChange From Baseline in AROM for Internal Rotation in the Affected Shoulder

AROM for internal rotation was measured using a goniometer and a spinal level. Positive change from Baseline means an improvement.

Time frame:
Baseline, Days 22, 43, 64, and 95
Reported as:
Mean · degrees
Change From Baseline in AROM for Internal Rotation in the Affected Shoulder
degreesEN3835Placebo
Day 227.5 ± 20.455.8 ± 19.12
Day 439.1 ± 22.1310.2 ± 20.40
Day 6418.4 ± 22.4417.5 ± 21.55
Day 9519.6 ± 21.9921.6 ± 23.87
SecondaryChange From Baseline in AROM for External Rotation in the Affected Shoulder

AROM for external rotation was measured using a goniometer. Positive change from Baseline means an improvement.

Time frame:
Baseline, Days 22, 43, 64, and 95
Reported as:
Mean · degrees
Change From Baseline in AROM for External Rotation in the Affected Shoulder
degreesEN3835Placebo
Day 225.3 ± 16.855.6 ± 14.79
Day 438.7 ± 19.5910.0 ± 19.12
Day 6413.9 ± 22.1815.4 ± 21.65
Day 9516.8 ± 21.6716.1 ± 21.00
SecondaryChange From Baseline in AROM for Abduction in the Affected Shoulder

AROM for abduction was measured using a goniometer. Positive change from Baseline means an improvement.

Time frame:
Baseline, Days 22, 43, 64, and 95
Reported as:
Mean · degrees
Change From Baseline in AROM for Abduction in the Affected Shoulder
degreesEN3835Placebo
Day 2214.2 ± 30.7513.7 ± 23.17
Day 4326.6 ± 37.7922.2 ± 27.93
Day 6437.2 ± 35.6033.3 ± 30.53
Day 9542.0 ± 37.7139.8 ± 31.79
SecondaryChange From Baseline in AROM for Shoulder Extension in the Affected Shoulder

AROM for shoulder extension was measured using a goniometer. Positive change from Baseline means an improvement.

Time frame:
Baseline, Days 22, 43, 64, and 95
Reported as:
Mean · degrees
Change From Baseline in AROM for Shoulder Extension in the Affected Shoulder
degreesEN3835Placebo
Day 227.0 ± 17.378.5 ± 15.84
Day 4313.7 ± 21.6312.0 ± 16.72
Day 6416.2 ± 19.2915.3 ± 16.70
Day 9519.7 ± 19.9117.3 ± 17.17
SecondaryChange From Baseline in AROM for Forward Flexion in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline

AROM for forward flexion was measured using a goniometer. AROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. AROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value

Time frame:
Baseline, Days 22, 43, 64, and 95
Reported as:
Mean · degrees
Change From Baseline in AROM for Forward Flexion in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline
degreesEN3835Placebo
Day 22-38.34 ± 30.007-40.72 ± 24.602
Day 43-31.00 ± 29.397-32.17 ± 24.879
Day 64-23.62 ± 29.115-23.82 ± 23.083
Day 95-19.83 ± 26.729-23.39 ± 24.774
SecondaryChange From Baseline in AROM for Internal Rotation in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline

AROM for internal rotation was measured using a goniometer and a spinal level. AROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. AROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value

Time frame:
Baseline, Days 22, 43, 64, and 95
Reported as:
Mean · degrees
Change From Baseline in AROM for Internal Rotation in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline
degreesEN3835Placebo
Day 22-30.53 ± 24.699-27.94 ± 24.757
Day 43-29.78 ± 24.728-23.45 ± 24.923
Day 64-20.57 ± 23.335-16.99 ± 24.708
Day 95-19.27 ± 23.646-12.66 ± 27.685
SecondaryChange From Baseline in AROM for External Rotation in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline

AROM for external rotation was measured using a goniometer. AROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. AROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value

Time frame:
Baseline, Days 22, 43, 64, and 95
Reported as:
Mean · degrees
Change From Baseline in AROM for External Rotation in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline
degreesEN3835Placebo
Day 22-34.78 ± 25.743-35.82 ± 22.666
Day 43-31.07 ± 29.543-31.23 ± 23.379
Day 64-25.31 ± 28.454-25.84 ± 26.291
Day 95-22.52 ± 26.313-25.42 ± 26.075
SecondaryChange From Baseline in AROM for Abduction in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline

AROM for abduction was measured using a goniometer. AROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. AROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value

Time frame:
Baseline, Days 22, 43, 64, and 95
Reported as:
Mean · degrees
Change From Baseline in AROM for Abduction in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline
degreesEN3835Placebo
Day 22-58.41 ± 38.888-57.28 ± 36.353
Day 43-46.14 ± 41.198-49.32 ± 34.988
Day 64-35.08 ± 36.868-39.82 ± 38.397
Day 95-30.74 ± 38.227-33.01 ± 39.718
SecondaryChange From Baseline in AROM for Shoulder Extension in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline

AROM for shoulder extension was measured using a goniometer. AROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. AROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value

Time frame:
Baseline, Days 22, 43, 64, and 95
Reported as:
Mean · degrees
Change From Baseline in AROM for Shoulder Extension in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline
degreesEN3835Placebo
Day 22-13.65 ± 19.893-15.25 ± 21.385
Day 43-7.55 ± 20.771-11.65 ± 20.674
Day 64-4.29 ± 20.214-6.94 ± 20.775
Day 95-1.00 ± 18.904-5.34 ± 20.922
SecondaryChange From Baseline in the Adapted ASES Composite Score

The adapted ASES is a self-administered participant reported outcome measure, divided into 2 sections: pain and function. Pain subscale is a single item, 11-point numeric rating scale, ranging from (no pain at all) to 10 (worst pain), calculated as 10 - pain raw score and multiplying by 5, score ranging from 0 (worst pain) to 50 (no pain). Function subscale consists of 10 activities, 4-point ordinal scale about their ability to do the activity with the affected arm, ranging from 0 (unable to do) to 3 (not difficult), calculated by multiplying the total score for 10 items by 5 and then dividing it by 3, score ranging from 0 (no function) to 50 (full function). The adapted ASES composite score is the sum of the pain subscale score (50% of the composite score) and function subscale score (50% of the composite score). The range for composite score is 0 (worst pain) to 100 (least pain). Positive change from Baseline score means an improvement in pain and/or shoulder function.

Time frame:
Baseline, Day 22, 43, and 64
Reported as:
Mean · score on a scale
Change From Baseline in the Adapted ASES Composite Score
score on a scaleEN3835Placebo
Day 2214.87 ± 15.68415.96 ± 14.269
Day 4325.15 ± 21.53221.77 ± 18.199
Day 6438.21 ± 22.83734.98 ± 21.222
SecondaryChange From Baseline in the Adapted ASES Function Subscale Score

The adapted ASES function subscale consists of 10 activities, 4-point ordinal scale about their ability to do the activity with the affected arm, ranging from 0 (unable to do) to 3 (not difficult), calculated by multiplying the total score for 10 items by 5 and then dividing it by 3, score ranging from 0 (worst no function) to 50 (full function). Positive change from Baseline score means an improvement in shoulder function.

Time frame:
Baseline, Day 22, 43, 64, and 95
Reported as:
Mean · score on a scale
Change From Baseline in the Adapted ASES Function Subscale Score
score on a scaleEN3835Placebo
Day 227.56 ± 8.2457.96 ± 7.388
Day 4312.82 ± 10.36511.77 ± 9.964
Day 6419.60 ± 12.12717.98 ± 11.337
Day 9521.05 ± 11.53820.73 ± 11.823
SecondaryChange From Baseline in the Adapted ASES Pain Subscale Score

The adapted ASES pain subscale is a single item, 11-point numeric rating scale, ranging from (no pain at all) to 10 (worst pain), calculated as 10 - pain raw score and multiplying by 5, score ranging from 0 (worst pain) to 50 (no pain). Positive change from Baseline score means an improvement in shoulder pain.

Time frame:
Baseline, Day 22, 43, 64, and 95
Reported as:
Mean · score on a scale
Change From Baseline in the Adapted ASES Pain Subscale Score
score on a scaleEN3835Placebo
Day 227.3 ± 9.618.0 ± 9.49
Day 4312.3 ± 12.7310.0 ± 11.87
Day 6418.6 ± 12.6717.0 ± 12.29
Day 9520.3 ± 13.1120.4 ± 12.28
SecondaryChange From Baseline in the Pain Upon Movement (PUM) Scale Score for the Affected Shoulder

The PUM scale is a single item 11-point numerical rating scale of pain in the affected shoulder after AROM forward flexion, internal rotation, external rotation, abduction, and shoulder extension on a scale from 0 (no pain at all) to 10 (pain as bad as it can be). A decrease from Baseline indicates improvement.

Time frame:
Baseline, Days 64 and 95
Reported as:
Mean · score on a scale
Change From Baseline in the Pain Upon Movement (PUM) Scale Score for the Affected Shoulder
score on a scaleEN3835Placebo
Day 64-3.6 ± 2.60-3.0 ± 2.72
Day 95-4.1 ± 2.59-3.8 ± 2.96
SecondaryChange From Baseline in Patient-reported Global Severity of Adhesive Capsulitis Scale

The Patient-reported Global Severity of Adhesive Capsulitis is a single item, 11-point numerical rating scale that asks participants to rate the overall severity of their adhesive capsulitis symptoms on a scale from 0 (no severity) to 10 (severe as can be). A decrease from Baseline indicates improvement.

Time frame:
Baseline, Day 22, 43, 64, and 95
Reported as:
Mean · score on a scale
Change From Baseline in Patient-reported Global Severity of Adhesive Capsulitis Scale
score on a scaleEN3835Placebo
Day 22-1.8 ± 1.84-1.5 ± 1.87
Day 43-3.0 ± 2.21-2.3 ± 2.16
Day 64-4.0 ± 2.41-3.6 ± 2.61
Day 95-4.4 ± 2.48-4.0 ± 2.87
SecondaryPatient-reported Change in Severity of Adhesive Capsulitis Scale

The Patient-reported Change in Severity of Adhesive Capsulitis is a questionnaire that asks participants if their adhesive capsulitis symptoms are "Better, About the Same, or Worse" since the last time the questionnaire was administered. Participants who reported that their symptoms are better or worse are then asked to rate the change in their symptoms on a 7-point ordinal scale for worse and better severity. An overall severity of worse was rated from 0 (almost the same, hardly worse at all) to -6 (a very great deal worse). An overall severity of better was rated from 0 (almost the same, hardly better at all) to 6 (a very great deal better). Only participants with a response of 'Worse' or 'Better' were analyzed. Participants with an overall severity response of 'About the same' were excluded from the summary table below. For overall worse severity, a lower score indicated a worse outcome. For overall better severity, a higher score indicated a better outcome.

Time frame:
Days 22, 43, 64 and 95
Reported as:
Mean · score on a scale
Patient-reported Change in Severity of Adhesive Capsulitis Scale
score on a scaleEN3835Placebo
Day 22: Worse Severity-3.4 ± 1.52-3.2 ± 2.23
Day 22: Better Severity2.4 ± 1.402.5 ± 1.29
Day 43: Worse Severity-3.3 ± 1.53-4.0 ± 2.16
Day 43: Better Severity3.4 ± 1.463.6 ± 1.44
Day 64: Worse Severity—-4.8 ± 0.50
Day 64: Better Severity4.5 ± 1.294.2 ± 1.40
Day 95: Worse Severity—-3.5 ± 1.91
Day 95: Better Severity4.7 ± 1.274.7 ± 1.09
SecondaryNumber of Responders Assessed With Investigator Assessment of Improvement

Investigator assessment of improvement with treatment in the severity of the participant's treated shoulder using a 7-point Likert scale from very much worse (-3) to very much improved (3). A responder was defined as a response of "very much improved", "much improved" or "minimally improved" in the investigator assessment of improvement with treatment.

Time frame:
Days 64 and 95
Reported as:
Count of participants · Participants
Number of Responders Assessed With Investigator Assessment of Improvement
ParticipantsEN3835Placebo
Day 647159
Day 958065
SecondaryNumber of Responders Assessed by the Subject Satisfaction With Treatment Assessment

Participants rated their satisfaction with treatment on a 7-point Likert scale from very dissatisfied (-3) to very satisfied (3) at specified times for relief of pain in treated shoulder, relief of stiffness in treated shoulder, relief of pain in treated shoulder compared to better shoulder, and relief of stiffness in treated shoulder compared to better shoulder. A responder was defined as a participant with a response of "very satisfied", "satisfied" or "somewhat satisfied" in the satisfaction with treatment.

Time frame:
Days 64 and 95
Reported as:
Count of participants · Participants
Number of Responders Assessed by the Subject Satisfaction With Treatment Assessment
ParticipantsEN3835Placebo
Day 64: Pain relief in treated shoulder8060
Day 64: Stiffness relief in treated shoulder7459
Day 64: Pain relief in treated shoulder compared to better shoulder7457
Day 64: Stiffness relief in treated shoulder compared to better shoulder7354
Day 95: Pain relief in treated shoulder7369
Day 95: Stiffness relief in treated shoulder7169
Day 95: Pain relief in treated shoulder compared to better shoulder7168
Day 95: Stiffness relief in treated shoulder compared to better shoulder6865
SecondaryNumber of Participants Positive for Anti-AUX-I and Anti-AUX-II Antibodies

Serum samples were collected and tested for the presence of anti-AUX-I and anti-AUX-II antibodies.

Time frame:
Day 95
Reported as:
Count of participants · Participants
Number of Participants Positive for Anti-AUX-I and Anti-AUX-II Antibodies
ParticipantsEN3835Placebo
Anti-AUX-I Antibodies833
Anti-AUX-II Antibodies813
SecondaryNumber of Participants Positive for Neutralizing Antibodies

Serum samples were collected and tested for the presence of anti-AUX-I and anti-AUX-II antibodies. Only samples positive for anti-AUX-I and anti-AUX-II antibodies were analyzed for neutralizing antibodies.

Time frame:
Day 95
Reported as:
Count of participants · Participants
Number of Participants Positive for Neutralizing Antibodies
ParticipantsEN3835Placebo
Neutralizing AUX-I Antibodies310
Neutralizing AUX-II Antibodies40

Adverse events

Collected over Day 1 (after dosing) through Day 95. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EN38350/101 (0%)1/101 (1%)69/101 (68.3%)
Placebo0/94 (0%)1/94 (1.1%)22/94 (23.4%)
Most frequent serious events
Most frequent serious events
EventEN3835Placebo
FallInjury, poisoning and procedural complications0/1011/94
DepressionPsychiatric disorders1/1010/94
Most frequent other events
Most frequent other events
EventEN3835Placebo
Injection site bruisingGeneral disorders47/1014/94
Injection site painGeneral disorders23/10110/94
ArthralgiaMusculoskeletal and connective tissue disorders23/10112/94
Injection site swellingGeneral disorders14/1012/94

Baseline characteristics

All randomized participants who received at least 1 injection of study treatment.

Age, Continuous
Age, Continuous(years)EN3835PlaceboTotal
Mean53.76 ± 7.56555.50 ± 7.80654.59 ± 7.712
Sex: Female, Male
Sex: Female, Male(Participants)EN3835PlaceboTotal
Female6566131
Male362864
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)EN3835PlaceboTotal
American Indian or Alaska Native123
Asian4610
Black121123
White8272154
Other Race224
Multiple Race011
Hispanic or Latino141630
Not Hispanic or Latino8778165
08

Study locations

38 sites
  • Endo Clinical Trial Site #38
    Birmingham, Alabama 32505, United States
  • Endo Clinical Trial Site #24
    Birmingham, Alabama 35243, United States
  • Endo Clinical Trial Site #9
    Mobile, Alabama 36609, United States
  • Endo Clinical Trial Site #29
    Tucson, Arizona 85712, United States
  • Endo Clinical Trial Site #12
    Encinitas, California 92024, United States
  • Endo Clinical Trial Site #16
    Huntington Beach, California 92647, United States
  • Endo Clinical Trial Site #18
    La Mesa, California 91942, United States
  • Endo Clinical Trial Site #14
    Pasadena, California 91105, United States
  • Endo Clinical Trial Site #37
    Denver, Colorado 80209, United States
  • Endo Clinical Trial Site #33
    Bradenton, Florida 34209, United States
  • Endo Clinical Trial Site #3
    Clearwater, Florida 33765, United States
  • Endo Clinical Trial Site #32
    Clermont, Florida 34711, United States
  • Endo Clinical Trial Site #13
    DeLand, Florida 32720, United States
  • Endo Clinical Trial Site #1
    Fort Lauderdale, Florida 33316, United States
  • Endo Clinical Trial Site #2
    Tampa, Florida 33606, United States
  • Endo Clinical Trial Site #20
    Winter Park, Florida 32789, United States
  • Endo Clinical Trial Site #34
    Dalton, Georgia 30720, United States
  • Endo Clinical Trial Site #26
    Lawrenceville, Georgia 30043, United States
  • Endo Clinical Trial Site #30
    Newnan, Georgia 30265, United States
  • Endo Clinical Trial Site #28
    Stockbridge, Georgia 30281, United States
  • Endo Clinical Trial Site #31
    Oak Brook, Illinois 60523, United States
  • Endo Clinical Trial Site #35
    New Orleans, Louisiana 70121, United States
  • Endo Clinical Trial Site #8
    Lincoln, Nebraska 68510, United States
  • Endo Clinical Trial Site #10
    Stony Brook, New York 11794, United States
  • Endo Clinical Trial Site #21
    Durham, North Carolina 27704, United States
  • Endo Clinical Trial Site #36
    Mooresville, North Carolina 28117, United States
  • Endo Clinical Trial Site #6
    Dayton, Ohio 45432, United States
  • Endo Clinical Trial Site #11
    Altoona, Pennsylvania 16602, United States
  • Endo Clinical Trial Site #7
    Indiana, Pennsylvania 15701, United States
  • Endo Clinical Trial Site #5
    State College, Pennsylvania 16801, United States
  • Endo Clinical Trial Site #17
    Bedford, Texas 76021, United States
  • Endo Clinical Trial Site #19
    Bellaire, Texas 77401, United States
  • Endo Clinical Trial Site #15
    Fort Worth, Texas 76104, United States
  • Endo Clinical Trial Site #27
    Georgetown, Texas 78628, United States
  • Endo Clinical Trial Site #25
    Laredo, Texas 78041, United States
  • Endo Clinical Trial Site #23
    Plano, Texas 75075, United States
  • Endo Clinical Trial Site #22
    Plano, Texas 75093, United States
  • Endo Clinical Trial Site #4
    Danville, Virginia 24541, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Apr 2022, 20 months.

Results were first posted in Sep 2023, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2020
First posted
Aug 3, 2020
StartActual
Jul 29, 2020
Primary completionActual
Apr 14, 2022
CompletionActual
Apr 14, 2022
Results first posted
Sep 13, 2023
Last update
Sep 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04496167
Responsible party
Sponsor
First posted
Aug 3, 2020
Start date
Jul 29, 2020
Primary completion
Apr 14, 2022
Completion
Apr 14, 2022
Results posted
Sep 13, 2023
Last update
Sep 13, 2023

Study contacts

Luis Ortega, MD
study director · Endo Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Microbial Collagenase

Start the discussion